Herve Yves Sroussi, D.M.S., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Calgranulin A | 7 | 2012 | 79 | 2.160 |
Why?
|
Lichen Planus, Oral | 8 | 2023 | 56 | 1.850 |
Why?
|
Xerostomia | 5 | 2021 | 95 | 1.540 |
Why?
|
Stomatognathic Diseases | 2 | 2020 | 21 | 1.410 |
Why?
|
Calgranulin B | 5 | 2011 | 84 | 1.400 |
Why?
|
Head and Neck Neoplasms | 5 | 2023 | 2732 | 1.170 |
Why?
|
Papillomavirus Infections | 5 | 2023 | 1587 | 1.170 |
Why?
|
Salivation | 2 | 2017 | 22 | 1.150 |
Why?
|
Mouth Diseases | 3 | 2020 | 241 | 1.110 |
Why?
|
Mouth Neoplasms | 9 | 2024 | 601 | 1.060 |
Why?
|
Neutrophils | 9 | 2021 | 3717 | 0.980 |
Why?
|
Sjogren's Syndrome | 3 | 2015 | 233 | 0.960 |
Why?
|
Oropharyngeal Neoplasms | 3 | 2023 | 477 | 0.910 |
Why?
|
Stomatitis | 3 | 2022 | 269 | 0.850 |
Why?
|
Dental Caries | 4 | 2022 | 415 | 0.820 |
Why?
|
Leukocyte L1 Antigen Complex | 2 | 2012 | 88 | 0.820 |
Why?
|
Candidiasis, Oral | 3 | 2012 | 60 | 0.800 |
Why?
|
Oncogene Proteins, Viral | 1 | 2023 | 362 | 0.790 |
Why?
|
Oral Hygiene | 2 | 2022 | 126 | 0.750 |
Why?
|
HIV Seropositivity | 2 | 2018 | 971 | 0.690 |
Why?
|
Neutrophil Activation | 2 | 2010 | 186 | 0.690 |
Why?
|
Carcinoma, Squamous Cell | 8 | 2024 | 4033 | 0.680 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 221 | 0.670 |
Why?
|
Diagnosis, Oral | 1 | 2018 | 23 | 0.660 |
Why?
|
Heart Valves | 1 | 2020 | 291 | 0.650 |
Why?
|
Periodontal Attachment Loss | 1 | 2018 | 141 | 0.620 |
Why?
|
Dental Care for Chronically Ill | 2 | 2007 | 33 | 0.620 |
Why?
|
Anti-Inflammatory Agents | 3 | 2020 | 1789 | 0.620 |
Why?
|
Coronavirus | 1 | 2020 | 158 | 0.610 |
Why?
|
Osteoradionecrosis | 1 | 2017 | 49 | 0.610 |
Why?
|
Sensation Disorders | 1 | 2017 | 156 | 0.570 |
Why?
|
Vitamin D Deficiency | 2 | 2018 | 1343 | 0.530 |
Why?
|
Poloxamer | 1 | 2015 | 57 | 0.520 |
Why?
|
Salivary Glands | 2 | 2015 | 229 | 0.520 |
Why?
|
Dimethylpolysiloxanes | 1 | 2015 | 149 | 0.490 |
Why?
|
Periodontal Diseases | 1 | 2017 | 449 | 0.470 |
Why?
|
Dexamethasone | 2 | 2022 | 1948 | 0.460 |
Why?
|
Tolonium Chloride | 2 | 2015 | 23 | 0.450 |
Why?
|
Vitamin D | 2 | 2020 | 3222 | 0.440 |
Why?
|
Heart Valve Diseases | 1 | 2020 | 1072 | 0.420 |
Why?
|
Receptor, PAR-2 | 1 | 2011 | 32 | 0.420 |
Why?
|
Oxidation-Reduction | 7 | 2012 | 2187 | 0.410 |
Why?
|
Precancerous Conditions | 3 | 2024 | 975 | 0.410 |
Why?
|
Leukoplakia, Oral | 4 | 2024 | 73 | 0.410 |
Why?
|
Preoperative Care | 1 | 2020 | 2246 | 0.390 |
Why?
|
Endotoxemia | 1 | 2012 | 206 | 0.390 |
Why?
|
Surgical Wound Infection | 1 | 2020 | 1540 | 0.380 |
Why?
|
Coloring Agents | 2 | 2015 | 566 | 0.360 |
Why?
|
Oligopeptides | 2 | 2012 | 1178 | 0.360 |
Why?
|
Communicable Diseases | 1 | 2017 | 880 | 0.330 |
Why?
|
Salivary Gland Diseases | 1 | 2007 | 37 | 0.300 |
Why?
|
Fluoresceins | 3 | 2011 | 235 | 0.280 |
Why?
|
DNA, Viral | 2 | 2023 | 2226 | 0.270 |
Why?
|
Candida albicans | 1 | 2008 | 394 | 0.260 |
Why?
|
Reactive Oxygen Species | 2 | 2010 | 2078 | 0.260 |
Why?
|
Wound Healing | 3 | 2014 | 2785 | 0.260 |
Why?
|
Cardiac Surgical Procedures | 1 | 2020 | 3533 | 0.260 |
Why?
|
Tacrolimus | 2 | 2022 | 743 | 0.260 |
Why?
|
Adenosine | 1 | 2010 | 825 | 0.250 |
Why?
|
Chemotaxis, Leukocyte | 2 | 2011 | 675 | 0.250 |
Why?
|
Down-Regulation | 1 | 2011 | 3001 | 0.240 |
Why?
|
Methionine | 1 | 2006 | 590 | 0.240 |
Why?
|
Antifungal Agents | 1 | 2008 | 730 | 0.240 |
Why?
|
Burning Mouth Syndrome | 1 | 2024 | 32 | 0.230 |
Why?
|
CD4 Lymphocyte Count | 2 | 2007 | 2559 | 0.230 |
Why?
|
Administration, Topical | 3 | 2022 | 689 | 0.220 |
Why?
|
Endocarditis, Bacterial | 1 | 2007 | 455 | 0.220 |
Why?
|
Lipopolysaccharides | 4 | 2012 | 2216 | 0.220 |
Why?
|
Lichenoid Eruptions | 1 | 2022 | 14 | 0.220 |
Why?
|
HIV Infections | 5 | 2011 | 16718 | 0.210 |
Why?
|
Recombinant Proteins | 5 | 2011 | 6612 | 0.210 |
Why?
|
Cyclosporins | 1 | 2022 | 220 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3132 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3239 | 0.210 |
Why?
|
Antibiotic Prophylaxis | 1 | 2007 | 638 | 0.210 |
Why?
|
Oral Medicine | 1 | 2021 | 31 | 0.200 |
Why?
|
Root Caries | 1 | 2021 | 16 | 0.200 |
Why?
|
Mucositis | 1 | 2022 | 101 | 0.190 |
Why?
|
Human papillomavirus 16 | 1 | 2023 | 262 | 0.190 |
Why?
|
Dysgeusia | 1 | 2020 | 14 | 0.190 |
Why?
|
Quality of Life | 3 | 2024 | 12805 | 0.190 |
Why?
|
Pandemics | 1 | 2020 | 8387 | 0.180 |
Why?
|
Humans | 44 | 2024 | 744220 | 0.170 |
Why?
|
Mutation, Missense | 1 | 2008 | 2563 | 0.170 |
Why?
|
Graft vs Host Disease | 2 | 2022 | 2957 | 0.170 |
Why?
|
Sepsis | 1 | 2012 | 2593 | 0.160 |
Why?
|
Education, Distance | 1 | 2021 | 251 | 0.150 |
Why?
|
Stress, Psychological | 2 | 2012 | 4245 | 0.150 |
Why?
|
Chicago | 1 | 2018 | 240 | 0.150 |
Why?
|
Inflammation Mediators | 1 | 2006 | 1889 | 0.150 |
Why?
|
Papillomaviridae | 2 | 2022 | 1119 | 0.150 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2011 | 657 | 0.140 |
Why?
|
N-Formylmethionine Leucyl-Phenylalanine | 2 | 2006 | 222 | 0.140 |
Why?
|
Skin | 2 | 2012 | 4363 | 0.140 |
Why?
|
Aged | 15 | 2022 | 163253 | 0.130 |
Why?
|
Emulsions | 1 | 2015 | 156 | 0.130 |
Why?
|
Middle Aged | 16 | 2024 | 213367 | 0.130 |
Why?
|
Enzyme Activation | 2 | 2011 | 3701 | 0.120 |
Why?
|
Mutagenesis, Site-Directed | 2 | 2008 | 1724 | 0.120 |
Why?
|
Aged, 80 and over | 6 | 2022 | 57768 | 0.120 |
Why?
|
Th1-Th2 Balance | 1 | 2013 | 38 | 0.110 |
Why?
|
Immunosuppressive Agents | 1 | 2006 | 4151 | 0.110 |
Why?
|
Nutrition Surveys | 1 | 2020 | 1660 | 0.110 |
Why?
|
RNA, Neoplasm | 2 | 2013 | 769 | 0.110 |
Why?
|
Survival Rate | 2 | 2020 | 12781 | 0.110 |
Why?
|
Mouth Mucosa | 1 | 2015 | 434 | 0.110 |
Why?
|
Female | 20 | 2024 | 380197 | 0.110 |
Why?
|
Fluorescent Dyes | 2 | 2010 | 1917 | 0.100 |
Why?
|
Epithelium, Corneal | 1 | 2014 | 247 | 0.100 |
Why?
|
Keratin-17 | 1 | 2011 | 26 | 0.100 |
Why?
|
Bacterial Load | 1 | 2012 | 153 | 0.100 |
Why?
|
Depsipeptides | 1 | 2011 | 94 | 0.100 |
Why?
|
Restraint, Physical | 2 | 2012 | 193 | 0.100 |
Why?
|
Inflammation | 2 | 2012 | 10634 | 0.100 |
Why?
|
Smoking | 3 | 2017 | 8986 | 0.100 |
Why?
|
Toll-Like Receptor 4 | 1 | 2014 | 567 | 0.100 |
Why?
|
Superinfection | 1 | 2011 | 65 | 0.100 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2011 | 1873 | 0.100 |
Why?
|
Cells, Cultured | 4 | 2011 | 19227 | 0.090 |
Why?
|
Case-Control Studies | 3 | 2022 | 21752 | 0.090 |
Why?
|
Fibrosis | 1 | 2017 | 2029 | 0.090 |
Why?
|
Purinergic P1 Receptor Antagonists | 1 | 2010 | 45 | 0.090 |
Why?
|
Radiotherapy | 1 | 2017 | 1525 | 0.090 |
Why?
|
beta 2-Microglobulin | 1 | 2011 | 315 | 0.090 |
Why?
|
Treatment Outcome | 5 | 2022 | 63119 | 0.090 |
Why?
|
Enzyme Activators | 1 | 2010 | 57 | 0.090 |
Why?
|
Receptors, Purinergic P1 | 1 | 2010 | 109 | 0.090 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 257 | 0.090 |
Why?
|
Drug Combinations | 1 | 2015 | 1962 | 0.090 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2012 | 362 | 0.090 |
Why?
|
Herpesviridae Infections | 1 | 2011 | 277 | 0.090 |
Why?
|
Cytodiagnosis | 1 | 2013 | 435 | 0.080 |
Why?
|
Steroids | 2 | 2022 | 931 | 0.080 |
Why?
|
DNA | 1 | 2023 | 7303 | 0.080 |
Why?
|
Time Factors | 3 | 2020 | 40063 | 0.080 |
Why?
|
Leukoplakia, Hairy | 1 | 2007 | 8 | 0.080 |
Why?
|
Stomatitis, Herpetic | 1 | 2007 | 12 | 0.080 |
Why?
|
Male | 15 | 2024 | 350027 | 0.080 |
Why?
|
Adenosine Deaminase | 1 | 2010 | 241 | 0.080 |
Why?
|
Th1 Cells | 1 | 2013 | 1057 | 0.080 |
Why?
|
Th2 Cells | 1 | 2013 | 1061 | 0.080 |
Why?
|
Voluntary Health Agencies | 1 | 2007 | 39 | 0.080 |
Why?
|
Warts | 1 | 2007 | 68 | 0.080 |
Why?
|
Adult | 13 | 2022 | 214035 | 0.080 |
Why?
|
Saliva, Artificial | 1 | 2006 | 5 | 0.070 |
Why?
|
Health Care Surveys | 1 | 2015 | 2453 | 0.070 |
Why?
|
Pharmaceutical Vehicles | 1 | 2006 | 59 | 0.070 |
Why?
|
Wound Infection | 1 | 2009 | 242 | 0.070 |
Why?
|
Mutant Proteins | 1 | 2008 | 500 | 0.070 |
Why?
|
Carboxymethylcellulose Sodium | 1 | 2006 | 39 | 0.070 |
Why?
|
Neutrophil Infiltration | 1 | 2009 | 390 | 0.070 |
Why?
|
Muscarinic Agonists | 1 | 2006 | 87 | 0.070 |
Why?
|
Prevalence | 2 | 2018 | 15226 | 0.070 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2006 | 300 | 0.070 |
Why?
|
Sex Factors | 1 | 2020 | 10396 | 0.070 |
Why?
|
Cholinergic Antagonists | 1 | 2006 | 165 | 0.070 |
Why?
|
Immunocompromised Host | 1 | 2011 | 847 | 0.070 |
Why?
|
Prospective Studies | 4 | 2024 | 53280 | 0.070 |
Why?
|
Loss of Heterozygosity | 1 | 2007 | 684 | 0.060 |
Why?
|
Protein Kinase C | 1 | 2010 | 1227 | 0.060 |
Why?
|
Cost of Illness | 1 | 2015 | 1859 | 0.060 |
Why?
|
Cell Movement | 4 | 2014 | 5216 | 0.060 |
Why?
|
United States | 4 | 2020 | 69867 | 0.060 |
Why?
|
Health Policy | 1 | 2017 | 2661 | 0.060 |
Why?
|
Anti-Infective Agents | 1 | 2011 | 972 | 0.060 |
Why?
|
Alanine | 1 | 2006 | 572 | 0.060 |
Why?
|
Cohort Studies | 2 | 2020 | 40559 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2022 | 5442 | 0.060 |
Why?
|
Cranial Irradiation | 1 | 2006 | 401 | 0.060 |
Why?
|
Receptors, Adrenergic, beta-2 | 1 | 2004 | 202 | 0.060 |
Why?
|
Chemotaxis | 1 | 2006 | 607 | 0.060 |
Why?
|
Antibodies | 1 | 2011 | 2461 | 0.060 |
Why?
|
Paresthesia | 1 | 2024 | 162 | 0.050 |
Why?
|
Fluocinonide | 1 | 2022 | 9 | 0.050 |
Why?
|
Microbial Sensitivity Tests | 1 | 2008 | 1877 | 0.050 |
Why?
|
Interferon Type I | 1 | 2006 | 542 | 0.050 |
Why?
|
Early Diagnosis | 1 | 2007 | 1184 | 0.050 |
Why?
|
Clobetasol | 1 | 2022 | 34 | 0.050 |
Why?
|
Erythema | 1 | 2023 | 257 | 0.050 |
Why?
|
Triamcinolone | 1 | 2022 | 68 | 0.050 |
Why?
|
Risk Factors | 4 | 2017 | 72280 | 0.050 |
Why?
|
Canada | 1 | 2007 | 2065 | 0.050 |
Why?
|
Cysteine | 1 | 2006 | 874 | 0.050 |
Why?
|
Cytokines | 2 | 2014 | 7326 | 0.050 |
Why?
|
Retrospective Studies | 4 | 2023 | 77426 | 0.050 |
Why?
|
Animals | 8 | 2021 | 168788 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2011 | 10949 | 0.050 |
Why?
|
Dentin | 1 | 2021 | 73 | 0.050 |
Why?
|
Point Mutation | 1 | 2006 | 1624 | 0.050 |
Why?
|
Piperazines | 1 | 2011 | 2491 | 0.050 |
Why?
|
Mice | 5 | 2014 | 81178 | 0.050 |
Why?
|
Streptococcus mutans | 1 | 2021 | 100 | 0.050 |
Why?
|
Gene Expression | 1 | 2014 | 7799 | 0.050 |
Why?
|
Rats | 2 | 2006 | 24273 | 0.040 |
Why?
|
Biopsy | 2 | 2013 | 6757 | 0.040 |
Why?
|
Hydroxychloroquine | 1 | 2023 | 412 | 0.040 |
Why?
|
Amino Acid Sequence | 1 | 2011 | 13817 | 0.040 |
Why?
|
Cross-Sectional Studies | 2 | 2018 | 25043 | 0.040 |
Why?
|
Peptides | 1 | 2011 | 4407 | 0.040 |
Why?
|
Enzyme Inhibitors | 1 | 2010 | 3800 | 0.040 |
Why?
|
Early Detection of Cancer | 1 | 2013 | 3086 | 0.040 |
Why?
|
Data Interpretation, Statistical | 1 | 2009 | 2715 | 0.040 |
Why?
|
Molecular Sequence Data | 1 | 2011 | 18116 | 0.040 |
Why?
|
Pain | 2 | 2024 | 4987 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12244 | 0.040 |
Why?
|
Prescriptions | 1 | 2021 | 387 | 0.040 |
Why?
|
Logistic Models | 1 | 2012 | 13409 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2015 | 15538 | 0.040 |
Why?
|
Kidney | 1 | 2012 | 7183 | 0.040 |
Why?
|
Liver | 1 | 2012 | 7472 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 4752 | 0.040 |
Why?
|
Pain Measurement | 1 | 2006 | 3419 | 0.040 |
Why?
|
Wounds and Injuries | 1 | 2009 | 2400 | 0.030 |
Why?
|
Chronic Disease | 2 | 2022 | 9147 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2006 | 5974 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2014 | 18027 | 0.030 |
Why?
|
Cell Migration Assays | 1 | 2014 | 23 | 0.030 |
Why?
|
Luminescence | 1 | 2015 | 137 | 0.030 |
Why?
|
Cattle | 1 | 2021 | 3922 | 0.030 |
Why?
|
Toll-Like Receptor 1 | 1 | 2014 | 48 | 0.030 |
Why?
|
Sex Characteristics | 1 | 2004 | 2586 | 0.030 |
Why?
|
Lung | 1 | 2012 | 9852 | 0.030 |
Why?
|
Chemokine CXCL1 | 1 | 2014 | 101 | 0.030 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2014 | 428 | 0.030 |
Why?
|
Bone Marrow Transplantation | 1 | 2022 | 2763 | 0.030 |
Why?
|
Areca | 1 | 2013 | 11 | 0.030 |
Why?
|
Decision Making | 1 | 2007 | 3888 | 0.030 |
Why?
|
HIV-1 | 1 | 2011 | 6938 | 0.030 |
Why?
|
Pilot Projects | 1 | 2006 | 8321 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2007 | 7784 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2014 | 489 | 0.030 |
Why?
|
Mice, Hairless | 1 | 2012 | 41 | 0.030 |
Why?
|
Ki-67 Antigen | 1 | 2014 | 644 | 0.030 |
Why?
|
Pertussis Toxin | 1 | 2011 | 178 | 0.030 |
Why?
|
Debridement | 1 | 2014 | 492 | 0.030 |
Why?
|
Respiratory Burst | 1 | 2011 | 113 | 0.030 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3584 | 0.020 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 697 | 0.020 |
Why?
|
Interleukin-8 | 1 | 2014 | 690 | 0.020 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2011 | 821 | 0.020 |
Why?
|
Herpesviridae | 1 | 2011 | 109 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2014 | 1799 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3278 | 0.020 |
Why?
|
Child | 2 | 2007 | 77679 | 0.020 |
Why?
|
Young Adult | 4 | 2021 | 56436 | 0.020 |
Why?
|
Health Care Costs | 1 | 2022 | 3209 | 0.020 |
Why?
|
Curriculum | 1 | 2021 | 3604 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2015 | 15070 | 0.020 |
Why?
|
Immunotherapy | 1 | 2024 | 4440 | 0.020 |
Why?
|
Aging | 1 | 2006 | 8661 | 0.020 |
Why?
|
Cricetinae | 1 | 2011 | 2472 | 0.020 |
Why?
|
Adolescent | 3 | 2014 | 85759 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 3871 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2013 | 13036 | 0.020 |
Why?
|
Blotting, Western | 1 | 2014 | 5180 | 0.020 |
Why?
|
Focus Groups | 1 | 2011 | 1321 | 0.020 |
Why?
|
Cell Line | 2 | 2014 | 15999 | 0.020 |
Why?
|
ROC Curve | 1 | 2013 | 3527 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2017 | 1797 | 0.020 |
Why?
|
Isoproterenol | 1 | 2004 | 399 | 0.020 |
Why?
|
Actins | 1 | 2011 | 2121 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2011 | 1782 | 0.010 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 1 | 2004 | 104 | 0.010 |
Why?
|
Virus Replication | 1 | 2011 | 2534 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2014 | 2958 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2014 | 3690 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2017 | 3158 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2014 | 10480 | 0.010 |
Why?
|
Incidence | 1 | 2017 | 20945 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2013 | 14726 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8426 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9438 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2014 | 21824 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 12075 | 0.010 |
Why?
|
Transcription Factors | 1 | 2014 | 12207 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2011 | 19907 | 0.010 |
Why?
|